Direct-acting antivirals: the endgame for hepatitis C?

• Published in: Current opinion in virology Vol. 24; pp. 31 - 37
• Main Authors: D’Ambrosio, Roberta, Degasperi, Elisabetta, Colombo, Massimo, Aghemo, Alessio
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2017
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - chemistry; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Disease Eradication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C - drug therapy; Hepatitis C - virology; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; Interferons - therapeutic use; Liver Cirrhosis - drug therapy; Liver Cirrhosis - virology; Male; Protease Inhibitors - therapeutic use; Ribavirin - therapeutic use; Viral Nonstructural Proteins - antagonists & inhibitors; Virus Replication - drug effects

•DAAs for HCV treatment include protease (NS3/4A) inhibitors, RNA-dependent polymerase (NS5B) inhibitors and NS5A inhibitors.•The combination of DAA owning to different classes have led to high SVR rates, independently on HCV genotype and fibrosis stage.•Treatment duration and RBV use depend from HC...